Colinz Laboratories Ltd
NSE: BSE: 531210
₹43.47
(4.75%)
Wed, 18 Mar 2026, 01:33 am
Market Cap104.54M
PE Ratio22.18
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KColinz Laboratories Analysis
dividend
- Unable to evaluate Colinz Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Colinz Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Colinz Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Colinz Laboratories is profitable, therefore cash runway is not a concern.
- Colinz Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (75.6%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 18.9x debt.
- Colinz Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (26% vs 4.3% today).
- Colinz Laboratories earns more interest than it pays, coverage of interest payments is not a concern.
- Colinz Laboratories's level of debt (4.3%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Colinz Laboratories board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- N.'s remuneration is lower than average for companies of similar size in India.
- N.'s compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
- The average tenure for the Colinz Laboratories management team is less than 2 years, this suggests a new team.
misc
- Colinz Laboratories is not covered by any analysts.
- Colinz Laboratories has significant price volatility in the past 3 months.
- BSE:531210 has not traded for 7 days.
past
- Colinz Laboratories's year on year earnings growth rate has been positive over the past 5 years.
- Colinz Laboratories has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Colinz Laboratories's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Colinz Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Colinz Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Colinz Laboratories's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Colinz Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
- 531210 outperformed the Market in India which returned -14.5% over the past year.
- Colinz Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Colinz Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Colinz Laboratories is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Colinz Laboratories is overvalued based on earnings compared to the India market.
- 531210 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- BSE:531210 is down -22.2% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:531210 is down -22.2% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800